Table I.
Patient disposition and baseline characteristics.
| Parameters | All patients (n=43) | Neoadjuvant setting (n=18) | Metastatic setting (n=25) |
|---|---|---|---|
| Age (years), mean ± SD, range | 55.14 ±10.7 (34-75) | 54.8±11.4 (34-73) | 55.3±10 (38-75) |
| BSA, kg/m2, mean ± SD | 1.54±0.2 | 1.6±0.2 | 1.54±0.24 |
| Sex, n (%) | |||
| Male | 31 (72.1) | 16 (88.9) | 15 (60) |
| Female | 12 (27.9) | 2 (11.1) | 10 (40) |
| Cancer Stage, n (%) | |||
| II | 6 (14.0) | 6 (33.3) | - |
| III | 10 (23.3) | 10 (55.6) | - |
| IV | 27 (62.8) | 2 (11.1) | 25 (100.0) |
| NDLS dose, n (%) | |||
| 75 mg/m2 | 37 (86.0) | 15 (83.3) | 22 (88.0) |
| 50 mg/m2 | 6 (14.0) | 3 (16.7) | 3 (12.0) |
| Metastasis site, n (%)a | |||
| Lymph node | 10 (23.3) | - | 10 (40.0) |
| Bone | 2 (4.7) | - | 2 (8.0) |
| Liver | 1 (2.3) | 1 (4.0) | |
| Line of therapy, n (%) | |||
| First-line | 38 (88.4) | 18 (100.0) | 20 (80.0) |
| Second-line | 4 (9.3) | - | 4 (16.0) |
| Third-line | 1 (2.3) | - | 1 (4.0) |
| ECOG performance score | |||
| 0 | 3 (7.0) | - | 3 (12.0) |
| 1 | 37 (86.0) | 18 (100.0) | 19 (76.0) |
| 2 | 3 (7.0) | - | 3 (12.0) |
| Comorbid disease, n (%) | |||
| Hypertension | 13 (30.2) | 2 (11.1) | 11 (44.0) |
| Diabetes | 5 (11.6) | 1 (5.6) | 4 (16.0) |
| Hypothyroidism | 5 (11.6) | 2 (11.1) | 3 (12.0) |
| Others | 3 (7.0) | 3 (16.7) | - |
Of the 43 patients included in this analysis, 39 had gastric cancer and 4 had GEJ. Cancer stage was confirmed by whole body positron emission tomography-computed tomography scan. Other comorbid diseases included asthma, coronary artery disease, thrombophlebitis and dyslipidemia. aMetastasis site was only available for 13 patients. GEJ, gastroesophageal junction; BSA, body surface area; ECOG, Eastern Cooperative Oncology Group; NDLS, nanosomal docetaxel lipid suspension; SD, standard deviation.